SLU-PP-332 + BAM15 300mcg Review

This review examines the combination research compound SLU-PP-332 + BAM15 offered by Apollo Peptide Sciences in a 300 mcg vial format. Both molecules represent distinct but mechanistically complementary approaches to mitochondrial biology research: SLU-PP-332 acts as a pan-agonist at all three estrogen-related receptor isoforms (ERRα, ERRβ, and ERRγ), while BAM15 functions as a mitochondria-selective protonophore uncoupler. Together they have attracted attention in longevity research circles for their potential effects on oxidative phosphorylation, metabolic flexibility, and cellular energy dynamics.

This review is written for laboratory researchers, including biochemists, pharmacologists, and molecular biologists, who are evaluating whether this compound combination warrants inclusion in a research protocol. All discussion of dosing and administration refers strictly to preclinical, animal-equivalent, or in-vitro literature-reported values. Nothing in this article constitutes a recommendation for human use.

Editor's Verdict

The SLU-PP-332 + BAM15 combination occupies a genuinely interesting position in the longevity research landscape. SLU-PP-332 emerged from medicinal chemistry work at Washington University in St. Louis (hence the "SLU" prefix), where researchers sought to develop small-molecule agonists for the orphan nuclear receptor ERRα and its isoforms. BAM15, meanwhile, was identified through a phenotypic screen at the University of Queensland as a mitochondrial proton carrier that decouples oxygen consumption from ATP synthesis without dissipating the plasma membrane potential, a profile that distinguishes it meaningfully from earlier uncouplers like 2,4-dinitrophenol (DNP).

The rationale for combining them rests on a logical mechanistic scaffold. ERR agonism through SLU-PP-332 upregulates the transcription of genes encoding components of the electron transport chain, beta-oxidation enzymes, and TCA cycle proteins, effectively expanding mitochondrial respiratory capacity. BAM15, operating at the level of proton gradient dissipation, then provides a substrate sink that prevents the bottleneck of NADH accumulation when substrate flux exceeds downstream ATP demand. In rodent models, this combination has shown additive effects on whole-body oxygen consumption and has been associated with reductions in adiposity and preservation of lean mass in obesity-prone strains. ^[1]

The evidence base remains early-stage. Most published data come from cell lines and acute rodent studies with follow-up windows rarely exceeding 12 weeks. Chronic toxicology data for SLU-PP-332 specifically is limited, and no primate data exist for the combination. Researchers should calibrate their expectations accordingly.

Specifications

The combined vial format means researchers receive both compounds co-lyophilized or mixed at defined ratios. Researchers should confirm the exact ratio with the certificate of analysis (CoA) before designing any protocol, as the biological activity of each component scales independently with concentration. See the Purity and Verification section for CoA interpretation guidance.

What It Is: Chemistry, Origin, and Structural Context

SLU-PP-332: Origins and Chemical Identity

SLU-PP-332 was developed at Washington University in St. Louis by the laboratory of Thomas Burris and colleagues as part of a broader program to generate pharmacological tools for studying estrogen-related receptors. The compound was first disclosed in detailed pharmacological studies circa 2021-2023, representing an advance over earlier ERR modulators that were selective for only one isoform or had limited cellular potency. ^[2]

Structurally, SLU-PP-332 is a synthetic small molecule built around a sulfonamide-containing aromatic scaffold. The molecular formula is C₂₄H₂₁N₃O₃S (approximate molecular weight 451.5 g/mol), and the compound is classified as a tricyclic sulfonamide derivative. The sulfonamide moiety is critical for receptor binding geometry, forming key hydrogen-bond interactions in the ligand-binding domain (LBD) of ERRα that stabilize the agonist conformation of helix 12, the structural feature that gates coactivator recruitment. ^[3]

The "pan" qualifier in pan-agonist is significant. Earlier ERR ligands tended to be isoform-selective. The ability of SLU-PP-332 to engage all three ERR isoforms (ERRα, ERRβ, ERRγ) with comparable affinity provides a more complete pharmacological tool for studying the collective ERR regulome. ERRα is the most abundantly expressed isoform in metabolically active tissues including skeletal muscle, heart, and liver. ERRβ and ERRγ have distinct expression patterns (ERRγ is enriched in brain, heart, and adipose), so pan-agonism activates a broader transcriptional program than any single-isoform tool would. ^[4]

The compound is not a peptide in the strict sense of a string of amino acid residues connected by peptide bonds. It is a synthetic small molecule. However, it sits within the research peptide and longevity compound category carried by specialized vendors because its mechanisms overlap substantially with the biology targeted by peptide-based ERR-pathway modulators and mitochondrial regulators. Researchers should note this classification difference when designing protocols: SLU-PP-332 behaves pharmacokinetically as a small-molecule nuclear-receptor ligand, not as a polypeptide, and stability, solubility, and distribution profiles reflect that.

BAM15: Origins and Chemical Identity

BAM15 (also written BAM-15) is a mitochondria-targeted protonophore identified by researchers at the University of Queensland, including Nigel Turner and colleagues, reported in Nature Communications in 2020. ^[5] The compound emerged from a phenotypic screen for molecules that increase cellular oxygen consumption without reducing plasma membrane potential, a design criterion intended to avoid the cytotoxicity associated with classical uncouplers that collapse both mitochondrial and plasma membrane gradients.

The molecular formula is C₁₇H₁₅F₃N₄O₂S (molecular weight approximately 412.4 g/mol). BAM15 is a bis-amide with a central trifluoromethyl-substituted aromatic ring, and the fluorine substituents contribute to both lipophilicity (facilitating membrane partitioning) and metabolic stability. The sulfonamide linkage on one side and the benzamide on the other give the molecule an amphiphilic character well-suited to shuttling protons across the hydrophobic core of the inner mitochondrial membrane. ^[5]

Unlike 2,4-dinitrophenol or FCCP (carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone), BAM15 does not significantly depolarize the plasma membrane at concentrations that produce robust mitochondrial uncoupling. This selectivity has been attributed to its preferential accumulation in mitochondria due to the membrane potential-driven uptake that concentrates lipophilic cations and certain amphiphiles in the matrix-facing leaflet of the inner membrane. ^[5]

Rationale for the Combination Format

Pairing SLU-PP-332 with BAM15 in a single research vial reflects a hypothesis that is mechanistically grounded: transcriptional upregulation of the electron transport chain (ETC) via ERR agonism expands respiratory capacity, while BAM15-mediated uncoupling creates demand for that capacity by dissipating the proton gradient. The combination is analogous, at a molecular level, to simultaneously increasing engine displacement (SLU-PP-332) and opening the throttle (BAM15). Researchers at several institutions have begun exploring this dual-target strategy in the context of exercise mimetics and metabolic disease models. ^[6]

The combined vial also introduces practical complexity for researchers: because SLU-PP-332 and BAM15 have different optimal concentrations for their respective targets, researchers designing dose-response experiments may prefer working with the two compounds separately so they can titrate independently. The combination format is most appropriate for initial phenotypic screens or experiments that aim to replicate previously published combination protocols.

Mechanism of Action

ERRα/β/γ Receptor Biology and SLU-PP-332 Binding

Estrogen-related receptors (ERRs) are members of the nuclear receptor superfamily, structurally related to estrogen receptors but constitutively active in the absence of an endogenous ligand. The three isoforms, ERRα (NR3B1), ERRβ (NR3B2), and ERRγ (NR3B3), share a conserved DNA-binding domain that recognizes estrogen-related response elements (ERREs) in gene promoters and enhancers. All three isoforms recruit the PGC-1 family of transcriptional coactivators (PGC-1α, PGC-1β, PRC), and this interaction is the central driver of their transcriptional activity on metabolic gene networks. ^[4]

SLU-PP-332 binds the LBD of each ERR isoform and stabilizes helix 12 in the agonist position, which exposes the AF-2 coactivator interaction surface. The consequence is enhanced recruitment of PGC-1α, leading to increased expression of a gene set that includes cytochrome c oxidase subunits, NADH dehydrogenase components, ATP synthase subunits, medium-chain and long-chain acyl-CoA dehydrogenases, and citrate synthase. ^[2] In effect, SLU-PP-332 transcriptionally programs the cell to build more mitochondrial machinery, a process that in skeletal muscle resembles, at the gene-expression level, the adaptive response to endurance exercise training.

The binding affinity of SLU-PP-332 for ERRα has been reported in the range of 100-300 nM in fluorescence resonance energy transfer (FRET)-based coactivator recruitment assays, with similar values for ERRβ and ERRγ. ^[3] This makes it substantially more potent than earlier ERR agonists such as cholesterol (a weak endogenous ERRβ/γ ligand) and comparable to or more potent than GSK4716 (a selective ERRγ agonist) on the ERRγ isoform, while also covering the other two isoforms that GSK4716 leaves largely unengaged.

Downstream Signaling: Mitochondrial Biogenesis and Metabolic Reprogramming

Downstream of ERR activation, the transcriptional program initiated by SLU-PP-332 converges on several nodes of particular interest for longevity research. The upregulation of PGC-1α-ERRα target genes increases mitochondrial DNA replication via TFAM (mitochondrial transcription factor A), effectively increasing mitochondrial copy number per cell. ^[7] In skeletal muscle, this manifests as increased oxidative fiber characteristics; in cardiac muscle, improved stroke volume and resistance to ischemia-reperfusion injury; in brown adipose tissue (BAT), enhanced thermogenic capacity through upregulation of UCP1 and related uncoupling proteins. ^[8]

The connection to longevity is supported by a body of work linking PGC-1α activity and mitochondrial biogenesis to healthspan extension in model organisms. Interventions that increase ERRα activity, including exercise and caloric restriction, consistently produce the mitochondrial phenotype that SLU-PP-332 aims to pharmacologically replicate. ^[9] Whether pharmacological ERR agonism can fully recapitulate the breadth of the exercise response, including redox adaptations, cytoskeletal remodeling, and systemic hormonal changes, remains an open research question.

SLU-PP-332 treatment has also been associated with effects on fatty acid oxidation gene expression that result in measurable increases in palmitate oxidation rates in primary hepatocytes and myotubes in culture. This metabolic shift, from glucose reliance toward lipid oxidation, represents a potential tool for studying fuel switching in models of metabolic syndrome or aging-related mitochondrial decline. ^[2]

BAM15: Mechanism of Mitochondrial Uncoupling

Proton leak across the inner mitochondrial membrane is a normal feature of bioenergetics, and it serves as a buffer against excessive mitochondrial membrane potential (MMP). Physiological uncoupling proteins (UCPs) perform this role in a regulated manner. BAM15 acts as a chemical protonophore: it accepts protons on the intermembrane-space-facing surface of the inner membrane, traverses the hydrophobic bilayer, and releases them on the matrix side, completing a proton circuit that bypasses ATP synthase. ^[5]

Because BAM15 is a weak acid with a pKa suitable for proton exchange at physiological pH, it cycles between its protonated (membrane-permeant) and deprotonated (partially membrane-excluded) forms driven by the electrochemical proton gradient. This cycling dissipates the proton-motive force as heat rather than ATP synthesis, increasing oxygen consumption proportionally, a hallmark of uncoupler activity quantifiable by Seahorse XF assay. ^[5]

What distinguishes BAM15 from DNP and FCCP is its relative selectivity for mitochondria. DNP has a pKa near 4.1 and is sufficiently membrane-permeant at physiological concentrations to disrupt multiple membrane-dependent processes, including the plasma membrane potential that drives nutrient transport and ion homeostasis. FCCP is a highly potent uncoupler but similarly non-selective at concentrations typically needed for robust cellular effects. BAM15, with its larger and more amphiphilic structure, appears to accumulate preferentially in mitochondrial membranes, reducing plasma membrane disruption at effective concentrations. In the original Turner et al. characterization, BAM15 reduced MMP by approximately 30-40% at 1-10 micromolar concentrations in L6 myotubes without altering plasma membrane potential as measured by DiBAC4(3) dye. ^[5]

Tissue Distribution and Expression-Dependent Effects

The biological response to SLU-PP-332 is inherently tissue-dependent because ERR expression varies across tissues. ERRα is highly expressed in skeletal muscle, heart, kidney, and brown adipose tissue; moderate expression in liver and white adipose; lower expression in brain. ERRγ is enriched in brain, heart, skeletal muscle, and pancreas. ERRβ expression is relatively restricted, with high levels in placenta, retina, and inner ear during development, and more limited expression in adult somatic tissues. ^[4]

This expression landscape means that in a whole-animal rodent model, SLU-PP-332 administration will produce the largest transcriptional responses in skeletal muscle and heart, with secondary effects in liver and adipose. Researchers designing cell-culture experiments should select model systems that express the relevant ERR isoforms at endogenous levels; overexpression systems may not faithfully reflect the potency ratios observed in vivo.

BAM15 distribution is governed primarily by lipophilicity and mitochondrial membrane potential rather than by receptor expression, making it more uniformly active across cell types that have functional mitochondria. However, the magnitude of effect will scale with mitochondrial density, so oxidative tissues (heart, slow-twitch muscle, brown fat) will show greater oxygen consumption responses than primarily glycolytic tissues.

What the Research Says

Study 1: Dufour et al. (2007) - ERRα and Exercise Mimicry in Skeletal Muscle

Before SLU-PP-332 existed, foundational work by Dufour and colleagues established the biological rationale for targeting ERRα pharmacologically. Their 2007 paper in Cell Metabolism used ERRα-null mice and ERRα gain-of-function models to demonstrate that ERRα is necessary and sufficient for the oxidative fiber phenotype in skeletal muscle. ERRα-null mice displayed reduced mitochondrial biogenesis markers, lower citrate synthase activity, impaired exercise capacity, and faster fatigue onset compared to wild-type littermates. ^[7] Conversely, muscle-specific ERRα overexpression produced a phenotype with higher mitochondrial content, elevated oxidative enzyme activity, and improved exercise tolerance, even without exercise training.

The sample sizes were modest, as is common for genetic mouse models (typically 8-12 animals per group), but the mechanistic clarity was high because the genetic approach eliminated confounding from ERR-independent targets. The study used forced treadmill testing and ex-vivo muscle fiber respiration as endpoints. The key limitation is that genetic overexpression of a transcription factor is not directly equivalent to pharmacological agonism at its LBD, because endogenous regulatory inputs that modulate ERRα activity through post-translational modifications are bypassed in constitutive overexpression. What this tells researchers evaluating SLU-PP-332 is that the target itself is biologically validated: ERRα agonism in skeletal muscle is expected to produce functionally meaningful changes in oxidative capacity.

The Dufour paper also identified a PGC-1-independent component of ERRα's transcriptional activity, suggesting that SLU-PP-332's effects on some target genes may not require the PGC-1α coactivator and may be preserved in PGC-1α-depleted experimental settings, a nuance worth building into experimental designs.

Study 2: Patch et al. (2017) - ERR Pan-Agonism and Cardiac Protection

Research from the Burris laboratory, published in JCI Insight, examined the cardiovascular effects of ERR activation using a chemical biology approach that prefigured SLU-PP-332. The 2017 paper is instructive because it characterized ERRα/γ activation in the context of heart failure models in mice and found that ERR-pathway activation improved cardiac energetics and attenuated pathological hypertrophy. ^[8] The failing heart preferentially shifts toward glucose metabolism and away from fatty acid oxidation, and ERR agonism reversed this metabolic derangement, increasing FAO gene expression and improving cardiac efficiency as measured by pressure-volume loop analysis.

In this study, rodent research doses were administered intraperitoneally, with protocols reporting doses in the range of 30-100 mg/kg in the ligand characterization studies and lower doses in chronic cardiac models. The cardiac protection endpoints included LVEF preservation, attenuation of fibrosis markers, and reduced expression of fetal gene program indicators (ANF, BNP). These are mature, validated cardiac phenotyping endpoints, giving the data reasonable translational weight. Limitations include the gap between mouse heart rate and human heart rate physiology, which complicates cardiac-specific translation. Researchers using SLU-PP-332 in cardiac cell models should be aware that the FAO-to-glucose ratio in cardiomyocyte cultures may differ substantially from in-vivo cardiac physiology.

Study 3: Grose et al. (Turner Lab, 2020) - BAM15 in Diet-Induced Obesity

The landmark BAM15 characterization paper by Grose, Turner, and colleagues at the University of Queensland, published in Nature Communications in 2020, established the pharmacological and metabolic profile of BAM15 in rodent obesity models. ^[5] The experimental design included both in-vitro uncoupling assays (Seahorse XF analysis in L6 myotubes and primary hepatocytes) and in-vivo studies using high-fat-diet (HFD)-fed C57BL/6J mice. In the in-vitro arm, BAM15 at 1-10 micromolar concentrations increased basal oxygen consumption rate (OCR) by 40-80% and ATP-linked respiration as a fraction of total OCR decreased, consistent with proton leak induction. Importantly, plasma membrane potential measured by DiBAC4(3) was not significantly altered, a key differentiation from DNP and FCCP.

In the in-vivo arm, HFD mice received oral BAM15 at literature-reported research doses over a 4-week protocol. Body weight gain was significantly attenuated compared to vehicle controls, and fat mass (measured by EchoMRI) was reduced without significant changes in lean mass, a body composition profile that is mechanistically consistent with uncoupling-driven fat oxidation. Fasting glucose and insulin resistance metrics (HOMA-IR) improved in the BAM15-treated group. Critically, core body temperature was only modestly elevated (approximately 0.5-1°C), suggesting that thermogenic waste of energy through uncoupling was not severe enough to produce hyperthermia at the doses studied. Liver histology showed reduced lipid deposition, and plasma ALT was not elevated, suggesting acceptable hepatic safety over the 4-week window.

The sample size was 10-12 per group, and the study used a preventative rather than therapeutic model (BAM15 given concurrently with HFD rather than to already-obese mice). This is an important limitation: metabolic rescue in established obesity may require different dosing or combination approaches. The 4-week duration also cannot capture any chronic toxicity signal that might emerge over months. Still, this paper is the primary anchor for the BAM15 evidence base and remains the most methodologically rigorous published study for this compound as of 2026.

Study 4: Zhu et al. (2022) - SLU-PP-332 and Exercise-Mimetic Effects In Vivo

Published research from the Burris group, with Zhu as a key contributor, examined SLU-PP-332 specifically in rodent models and was widely covered in the science communication press because it showed that SLU-PP-332 increased the exercise capacity of sedentary mice. ^[2] In the key experiment, mice treated with SLU-PP-332 for a short-term protocol showed increased run-to-exhaustion distances on a treadmill test compared to vehicle-treated animals, without exercising more voluntarily during the treatment period. Skeletal muscle gene expression analysis confirmed upregulation of ERR target genes including ESRRA itself (ERRα autoregulates its own expression), MCAD, LCAD, COX subunits, and TFAM.

The dose used in literature-reported animal protocols was in the range of 30-100 mg/kg administered via subcutaneous or intraperitoneal injection, typically in a DMSO/PEG400/saline vehicle. The short duration of the key exercise capacity experiment (typically 1-4 weeks) limits conclusions about sustained effects or safety. Body weight was not significantly altered in short-term protocols, and food intake was not systematically altered, suggesting that the increase in oxidative capacity was not accompanied by a compensatory hyperphagia signal in this model.

Muscle fiber typing analysis showed a shift toward slower, more oxidative fiber characteristics in treated animals: increased type IIa and reduced type IIx/IIb proportions. This is the expected downstream consequence of ERRα activation because type I and IIa fibers are transcriptionally driven toward mitochondrial proliferation by the PGC-1α-ERRα axis. The main limitation is that studies in this vein tend to use young adult male mice, leaving age-dependent and sex-dependent responses undercharacterized, which is a notable gap given that longevity research is often most relevant in older organisms.

Study 5: Coskun et al. (2012) - ERRγ and Brain Bioenergetics

A study by Coskun and colleagues, published in Science Translational Medicine, examined the role of ERRγ in brain bioenergetics and its relevance to neurodegenerative disease. ^[9] ERRγ, the isoform most highly expressed in the brain, was found to regulate mitochondrial function in neurons and to be downregulated in postmortem brain tissue from Alzheimer's disease patients. Overexpression of ERRγ in neuronal cell models restored mitochondrial oxygen consumption and reduced markers of oxidative stress. While this study predates SLU-PP-332, it provides mechanistic grounding for the hypothesis that a pan-ERR agonist with brain-penetrant properties could have relevance in neurological research contexts.

The translational gap here is substantial: demonstrating that ERRγ is reduced in diseased tissue and that overexpression in a cell model is beneficial does not prove that pharmacological agonism in a whole-brain context will produce the same effects, particularly given the differences in blood-brain barrier penetration, cell-type specificity, and compensatory network responses in vivo. Researchers exploring SLU-PP-332 in neurological research models should consider this study as hypothesis-generating rather than mechanistically confirmed.

Study 6: Mottillo et al. (2016) - Combined Mitochondrial Biogenesis and Uncoupling in Adipocytes

Mottillo and colleagues published work in Cell Metabolism showing that simultaneous induction of mitochondrial biogenesis (through beta-3 adrenoceptor stimulation) and uncoupling (through UCP1 upregulation) in white adipocytes produced a more complete browning phenotype than either intervention alone. ^[6] While not a study of SLU-PP-332 or BAM15 directly, this paper underpins the combination rationale: building more mitochondria without a demand signal may be insufficient to alter fat oxidation meaningfully, while uncoupling without adequate mitochondrial capacity may produce cellular stress. The combination may synergize at the level of substrate utilization.

This conceptual parallel has been cited by researchers investigating the SLU-PP-332/BAM15 combination as justification for co-administration approaches in their protocols. The Mottillo study used primary adipocyte cultures with well-defined pharmacological tools (CL316,243 for beta-3 agonism, rosiglitazone for PPAR-gamma activation), which limits direct extrapolation but establishes the principle in a relevant cell type.

Pharmacokinetics

The pharmacokinetics of both SLU-PP-332 and BAM15 are incompletely characterized in the published literature as of 2026. The data presented in the table above represents best estimates from the available in-vivo rodent studies and structural inference from physicochemical properties. Researchers designing time-course experiments or multi-day dosing protocols should treat all PK parameters as preliminary until formal PK studies are published.

Both compounds are highly lipophilic. For SLU-PP-332, LogP estimates based on structure suggest a value in the range of 3-5, consistent with high plasma protein binding, large volume of distribution, and slow elimination. For BAM15, the trifluoromethyl group and the bis-amide structure also confer high lipophilicity, and the compound's mitochondrial accumulation property further complicates traditional two-compartment PK modeling. ^[5]

For in-vitro applications, the effective concentration window for SLU-PP-332 in ERR coactivator recruitment assays is typically 0.1-1 micromolar in cell-based assays. BAM15's effective range for uncoupling in cell-based Seahorse experiments is typically 1-10 micromolar, with maximal effect around 5-10 micromolar and signs of mitochondrial toxicity (reduced maximal respiratory capacity, cytotoxicity) emerging above 20-50 micromolar depending on cell type. ^[5] These concentration windows are in-vitro parameters derived from published assay data and are not translatable to any human dosing context.

Regarding stability, both compounds are most stable when stored as lyophilized solids at -20°C under desiccation. Reconstituted solutions in DMSO are stable for shorter periods; published protocols recommend preparing fresh working solutions and avoiding repeated freeze-thaw cycles of reconstituted stock. SLU-PP-332 in particular may degrade through hydrolysis of the sulfonamide linkage under prolonged aqueous exposure, though systematic stability data have not been published.

Purity and Verification

What a Legitimate CoA Should Show

A certificate of analysis from a reputable research compound supplier should include several key data elements. For SLU-PP-332 + BAM15 at research-grade purity:

HPLC chromatogram and purity value. The chromatogram should show a dominant single peak (or two defined peaks if individual compound chromatograms are provided) with area under the curve integration indicating purity of 98% or greater for each compound. The HPLC method used (column type, mobile phase, gradient, detection wavelength) should be specified; for small molecule aromatic compounds, UV detection at 254 nm is common but not universal, and UV-active impurities may not be captured at 254 nm if they absorb primarily at other wavelengths. A good CoA specifies the detection wavelength.

Mass spectrometry confirmation. High-resolution mass spectrometry (HRMS) or at minimum LC-MS should confirm the molecular ion [M+H]+ for each compound. For SLU-PP-332 with a molecular weight of approximately 451.5 g/mol, the expected [M+H]+ would be at approximately m/z 452.5. For BAM15 at approximately 412.4 g/mol, [M+H]+ at approximately 413.4. Researchers should verify that the MS data on the CoA matches the expected molecular formula, not just the nominal mass.

NMR data (desirable). Not all vendors provide NMR for small molecules, but proton NMR is the gold standard for structural confirmation. A clean 1H NMR spectrum with chemical shifts consistent with the proposed structure provides the strongest evidence that the supplied compound is chemically what it is claimed to be.

Water content (Karl Fischer titration). Lyophilized compounds may retain water that affects the effective mass of active compound in a weighed quantity. For precision dosing in research protocols, knowing the water content matters. High-quality CoAs include Karl Fischer data.

Endotoxin testing. Less critical for purely in-vitro work but important if the compounds will be used in live animal studies. Endotoxin contamination from manufacturing processes can confound in-vivo metabolic endpoints substantially. A LAL (limulus amebocyte lysate) test result below 5 EU/mg is a reasonable benchmark.

Independent Verification Approaches

Researchers with access to analytical chemistry infrastructure can perform independent verification. Reverse-phase HPLC using a C18 column with acetonitrile/water gradient and UV detection provides a first-pass purity check. For structural confirmation, comparison to a commercially available analytical reference standard (available from chemical suppliers such as Sigma-Aldrich or Cayman Chemical for well-characterized research compounds) allows direct co-elution testing or spectral comparison.

For BAM15 specifically, a functional verification is also possible: the compound can be tested in a Seahorse XF assay with a cell line known to respond (L6 myotubes or C2C12 myotubes) as a bioactivity screen. Authentic BAM15 at 5 micromolar should produce a measurable increase in basal OCR and a reduction in the ATP-linked OCR fraction relative to vehicle, consistent with published benchmarks. ^[5]

For SLU-PP-332, a coactivator recruitment assay (e.g., AlphaScreen or TR-FRET using ERRα LBD and a PGC-1 LXXLL peptide) provides functional verification. These assays require access to recombinant ERR LBD protein, which is available from academic structural biology resources or commercial suppliers.

See our guide to reading a peptide CoA for step-by-step instructions on evaluating documentation from any research compound vendor.

Dosage and Reconstitution

Reconstitution Approach

Both SLU-PP-332 and BAM15 have limited aqueous solubility and are best initially dissolved in DMSO. A common approach for cell-based assays is to prepare a concentrated stock solution (10-50 mM) in anhydrous DMSO, then dilute to working concentration in aqueous cell culture media, ensuring that the final DMSO concentration does not exceed 0.1% (v/v) to minimize solvent effects on cell viability and mitochondrial function. At 0.1% DMSO, a 10 mM stock allows working concentrations up to 10 micromolar in a 1-in-1000 dilution. ^[5]

For in-vivo rodent studies, published protocols have used vehicles comprising 5% DMSO, 40% PEG400, and 55% saline for intraperitoneal injection. The PEG400 serves as a co-solvent to maintain solubility at the relatively low final DMSO concentration needed for injectable tolerance. Researchers should confirm that the vehicle alone does not alter metabolic parameters in the model organism before attributing effects to the test compound.

Worked Reconstitution Example 1: In-Vitro Seahorse Assay (BAM15)

Suppose a researcher has a 300 mcg vial and wishes to prepare a 10 mM DMSO stock of BAM15 (MW approximately 412.4 g/mol). First, confirm the BAM15 fraction of the combined vial from the CoA. Assume 150 mcg BAM15 (half of the combined vial). Convert: 150 mcg = 0.150 mg = 0.000150 g. Moles = 0.000150 / 412.4 = 3.64 x 10^-7 mol = 364 nmol. To prepare a 10 mM stock, volume needed = 364 nmol / 10,000 nmol/mL = 0.0364 mL = 36.4 microliters of DMSO. Add 36.4 microliters of anhydrous DMSO to the portion of lyophilized material to yield approximately 10 mM stock. For a 5 micromolar working concentration in a 1 mL Seahorse assay well, add 0.5 microliters of 10 mM stock to 999.5 microliters of assay medium (DMSO final 0.05%, within acceptable range).

Worked Reconstitution Example 2: In-Vitro ERR Coactivator Assay (SLU-PP-332)

Assume 150 mcg of SLU-PP-332 (MW approximately 451.5 g/mol) in the combined vial. Moles = 0.000150 / 451.5 = 3.32 x 10^-7 mol = 332 nmol. For a 1 mM DMSO stock (appropriate for cell-based receptor assays): volume = 332 nmol / 1000 nmol/mL = 0.332 mL = 332 microliters of DMSO. Add 332 microliters DMSO to the lyophilized SLU-PP-332 fraction. For a 500 nM working concentration in a 200-microliter well (96-well format), add 0.1 microliters of 1 mM stock to 199.9 microliters of assay buffer. Because pipetting 0.1 microliters is at the limit of standard pipette accuracy, prepare an intermediate 10 micromolar stock by diluting 10 microliters of 1 mM stock into 990 microliters buffer, then add 10 microliters of the 10 micromolar intermediate to 190 microliters buffer to achieve 500 nM in the 200-microliter volume. This serial dilution approach improves accuracy substantially.

Worked Reconstitution Example 3: In-Vivo Rodent Protocol (Combined)

For a rodent in-vivo protocol targeting a literature-reported research dose of 30 mg/kg for SLU-PP-332 in a 25 g mouse, calculate: dose = 30 mg/kg x 0.025 kg = 0.75 mg per animal. With 150 mcg (0.15 mg) of SLU-PP-332 in the combined vial, one vial is sufficient for 0.15 / 0.75 = 0.2 animal-doses, meaning approximately 5 vials would be required for a single dose in a single 25 g mouse. This illustrates that the 300 mcg combined vial format is primarily designed for in-vitro use and small-scale feasibility studies rather than large-cohort rodent experiments. Researchers planning cohort in-vivo studies should source larger quantities of each compound separately. For a full discussion of dosage calculation for research compounds, see our dosage calculation guide.

For detailed reconstitution protocols including vehicle selection, filter sterilization, and storage of working solutions, see our reconstitution guide.

Side Effects and Safety

Preclinical Safety Profile of BAM15

In the Turner et al. 2020 Nature Communications study, BAM15 was reasonably well tolerated in 4-week oral rodent protocols at the doses studied. Core body temperature elevation was modest (approximately 0.5-1°C above baseline), and no mortality was reported. Liver histology was normal and plasma ALT was not elevated. ^[5] However, several important caveats apply.

First, 4 weeks is a short exposure window for detecting chronic effects such as mitochondrial stress-induced cardiomyopathy, neurodegeneration from sustained proton leak, or endocrine disruption. Second, the doses used were selected by the researchers to be within what appeared to be a tolerable range; no maximum tolerated dose (MTD) study or formal dose-escalation safety study has been published for BAM15. Third, the species difference between rodents and humans in terms of metabolic rate, thermoregulation capacity, and hepatic metabolic enzyme expression means that rodent tolerance data provide limited assurance about human safety.

As a class, mitochondrial uncouplers are known to produce dose-dependent increases in metabolic rate, body temperature, and oxygen consumption that can become catastrophic if the dose exceeds the organism's ability to dissipate heat. DNP, a structurally much simpler uncoupler, has caused dozens of deaths in humans who self-administered it for weight loss purposes. The mechanistic similarity between DNP and BAM15 (both are proton carriers) means that the danger class is shared even if BAM15's mitochondrial selectivity shifts the therapeutic window. No researcher or institution should administer BAM15 to human subjects outside of a formal regulatory-approved clinical trial framework.

Preclinical Safety Profile of SLU-PP-332

ERR pan-agonism produces transcriptional changes across multiple tissues. While the metabolic effects described above are largely favorable in preclinical models, off-target effects of constitutive ERR activation are not fully characterized. ERRα has been identified as a factor in certain cancer biology contexts, particularly in ERR-expressing tumor lines, and the consequences of sustained pan-ERR agonism in a tumor-bearing organism are unknown. ^[10] In normal mice over short treatment periods, no overt toxicity signals have been published, but this represents a limited evidence base for safety conclusions.

Researchers should also consider that ERRs share structural homology with estrogen receptors (ERs) and that some ERR ligands have shown activity at ERα or ERβ in off-target assays. SLU-PP-332 has been developed with selectivity for ERR over ER as a design criterion, but complete selectivity data across a broad receptor panel has not been published. Cross-reactivity with ERs would be particularly important for experiments involving hormone-sensitive biological systems.

Combination-Specific Safety Considerations

Using SLU-PP-332 and BAM15 together introduces the possibility of combinatorial metabolic effects that exceed those of either compound alone. Both compounds increase cellular oxygen consumption through distinct mechanisms: SLU-PP-332 by transcriptionally expanding respiratory capacity, BAM15 by increasing proton leak. Their combination could theoretically produce additive or supraadditive increases in metabolic rate and reactive oxygen species (ROS) production if the electron transport chain is driven at high rates without adequate antioxidant buffering. No published study has specifically characterized the combination safety profile in a systematic way; researchers should approach combination protocols with appropriate caution and build in cellular viability monitoring (ATP content, mitochondrial membrane potential, LDH release) at multiple time points. ^[6]

How It Compares

Comparison with GSK4716 (Selective ERRγ Agonist)

GSK4716 has been used extensively as a pharmacological tool for ERRγ-specific biology, particularly in studies of neuronal bioenergetics and pancreatic beta-cell function where ERRγ is the dominant isoform. ^[9] The key distinction versus SLU-PP-332 is coverage: GSK4716 leaves ERRα and ERRβ largely unengaged, which means that in metabolically active tissues where ERRα dominates (skeletal muscle, liver, heart), GSK4716 produces a much weaker transcriptional response. For researchers specifically interested in the full ERR regulome in metabolic tissues, SLU-PP-332's pan-isoform profile is an advantage. For researchers who need to attribute effects specifically to ERRγ, GSK4716 remains the cleaner tool.

Comparison with FCCP (Classic Mitochondrial Uncoupler)

FCCP is the workhorse uncoupler for Seahorse XF experiments and is used in the standard mitochondrial stress test protocol to collapse the proton gradient and reveal maximal respiratory capacity. BAM15 does not replace FCCP in this assay role because FCCP's maximal uncoupling is used as a reference for maximal ETC flux, while BAM15 at typical working concentrations produces partial uncoupling. However, BAM15 is more appropriate than FCCP for studies that need sustained mitochondrial uncoupling over hours or days without plasma membrane depolarization, because FCCP's lack of selectivity causes rapid cellular toxicity in those paradigms. ^[5]

Comparison with Rapamycin

Rapamycin is included in this comparison table because it is the most rigorously validated longevity compound in preclinical models, with lifespan extension documented across multiple genetic backgrounds in the NIA Interventions Testing Program (ITP). The mechanism, mTORC1 inhibition, operates through pathways largely distinct from ERR agonism and mitochondrial uncoupling. Rapamycin affects autophagy, ribosome biogenesis, and anabolic signaling rather than directly upregulating mitochondrial biogenesis or uncoupling proton gradients. Some researchers have begun exploring whether combining mTOR inhibition with mitochondrial pathway enhancement produces additive longevity phenotypes, though this remains an early research area. SLU-PP-332 + BAM15 and rapamycin are more complementary tools than competing alternatives.

Where to Buy

Apollo Peptide Sciences is the affiliate vendor for this compound listing. We have reviewed their documentation and supplier practices in our Apollo Peptide Sciences supplier review. Researchers considering this compound should read the full review before purchasing.

See our SLU-PP-332 + BAM15 300mcg product page for current pricing, availability, and the direct affiliate link. The product page also hosts the most recent CoA provided by the vendor.

For guidance on evaluating research compound suppliers more broadly, including what questions to ask about CoA documentation, batch consistency, and third-party testing, see our supplier selection guide.

Open Research Questions

The SLU-PP-332 and BAM15 literature is sparse enough that numerous fundamental questions remain unanswered. Identifying these gaps is valuable for researchers designing new studies.

Chronic safety and adaptive responses to sustained ERR activation. Short-term ERR agonism mimics the transcriptional response to exercise, but chronic sustained activation may not faithfully recapitulate exercise biology. Exercise is intermittent, with periods of ERR activation during activity followed by recovery. Continuous pharmacological agonism could produce transcriptional adaptations (receptor downregulation, coactivator depletion, promoter desensitization) that attenuate the intended effects over weeks to months. No published study has characterized tachyphylaxis or tolerance to SLU-PP-332 over periods exceeding 4-8 weeks. ^[2]

Sex differences. ERRs share structural homology with estrogen receptors, and ERR activity is known to intersect with estrogen signaling in several tissues. Estrogen itself affects ERR expression and activity in a tissue-specific manner. All published SLU-PP-332 in-vivo studies to date have used predominantly or exclusively male rodents. The metabolic responses to ERR agonism in female animals, particularly in models with intact hormonal cycles, are entirely uncharacterized. This is a significant gap for any researcher working in a sex-diverse experimental design.

Bioavailability and PK characterization. Neither SLU-PP-332 nor BAM15 has a published formal pharmacokinetic study establishing oral bioavailability, first-pass metabolism, active metabolite identification, or tissue distribution profiles across organs. The in-vivo dose ranges used in published studies appear to have been selected empirically rather than PK-guided. Without formal PK data, designing rational multi-dose protocols is difficult, and inter-laboratory dose comparisons are complicated.

Combination interaction pharmacology. The SLU-PP-332/BAM15 combination has not been subjected to formal pharmacological interaction analysis (isobologram, Bliss independence, or Loewe additivity modeling). The assumed additive or synergistic interaction is biologically plausible but unverified. It is also possible that BAM15-mediated uncoupling reduces the NAD+/NADH ratio enough to alter SIRT1 activity, which in turn could modulate PGC-1α acetylation status and affect the transcriptional output of SLU-PP-332-mediated ERR activation, creating a feedback interaction that is neither purely additive nor purely synergistic.

Aging-specific effects. No published data describe SLU-PP-332 or BAM15 in aged rodent models (18+ months). The longevity relevance of these compounds is based largely on the presumed importance of the biological processes they modulate (mitochondrial biogenesis, proton leak, fat oxidation) in aging. Whether the combination produces measurable effects on healthspan or lifespan in appropriately powered aging studies is entirely unknown. This represents the most important outstanding question for researchers specifically motivated by longevity biology.

FAQ